Naxpar Pharma is a finished-dose manufacturer based in India. It appears in 18 regulatory filings across 5 regulators, without an active US DMF or CEP on file. Its filings concentrate with DIGEMAPS (DO), CDSCO (India) and NAFDAC (NG). Its GMP standing is certified by CDSCO (India) and NAFDAC (NG). Customs aggregates show $22K of exports covering 1 molecule to 1 destination in 2025.
| Site | FDA FEI |
|---|---|
| Dist.Solan, United Arab Emirates | Not on file |
| sura t 394 230surat, India | Not on file |
| G.I.D.C., India | Not on file |
| Baddi, Nigeria | Not on file |
| Regulator | Filings | GMP certificates |
|---|---|---|
| DIGEMAPS (DO) | 7 | None |
| CDSCO (India) | 4 | 2 |
| NAFDAC (NG) | 3 | 1 |
| MINSA (CR) | 3 | None |
| EDE (AE) | 1 | None |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | Not reported | $22K | 1 |
| 2024 | Not reported | $13K | 1 |
| 2023 | Not reported | $40K | 2 |
| 2022 | Not reported | $584K | 3 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Naxpar Pharma comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.